In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.
Alison Gorman
Advertisement
Alison Gorman recently joined Dermatology Times as a content producer. She is a registered nurse and spent more than a decade as a TV news health reporter. She also served four years as a Nurse Corps Officer in the United States Navy.
You can reach Alison via email at: agorman@mjhlifesciences.com
Articles by Alison Gorman
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
2
Roflumilast Eases Sexual Difficulties in Psoriasis With Genital Involvement
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
Managing Treatment Expectations in Hidradenitis Suppurativa: What to Tell Patients Before Starting Therapy
5